News & Events

≪ Back to All News & Events

October 06, 2010

More than 60 innovative medical technology companies have been competitively selected to present company profiles

More than 60 innovative medical technology companies have been competitively selected to present company profiles

More than 60 innovative medical technology companies have been competitively selected to present company profiles before potential investors, partners and industry stakeholders, October 19 and 20 at AdvaMed 2010: The MedTech Conference. Selected companies represent innovation at all stages of development from various medical device sectors, and come from across the United States, Austria, Canada, Chile, Israel, Luxembourg, Switzerland and the United Kingdom. New this year are 20 company presentations from Coulter Foundation Translational Research Partnership Universities and two “Funding Forums” to highlight venture capital and government funding opportunities for emerging growth and established companies.

“We have selected a diverse group of companies with technologies that range from addressing traumatic brain injuries with medical neurotechnology to photonic tumor therapy and everything in-between,” said Etienne Lagace, a Principal of Inovia Healthcare Ventures of Canada and a member of the AdvaMed 2010 company presentation selection committee. “These presentations and funding forums will provide companies with insights into the latest and most innovative technologies of today and tomorrow, as well as the funding opportunities available to develop these new, life saving and life changing medical devices. As an investor and an industry stakeholder, I look forward to hearing from all the companies and academic entrepreneurs.”

AdvaMed 2010 presenting companies include the following:

  • 4ibio, Pickering, Ontario, Canada
  • 20/20 GeneSystems, Inc., Rockville, Maryland
  • Activiews, Inc., Lynnfield, Massachusetts
  • Advanced Dental Technology, Richmond, Virginia
  • Altrika, Inc. Sheffield, United Kingdom
  • Alverix, Inc., San Jose, California
  • AMES Technology, Inc., Portland, Oregon
  • Avancen MOD Corporation, Mount Pleasant, South Carolina
  • Biocompatibles International plc., Farnham, United Kingdom
  • BrainScope Company, Inc., Bethesda, Maryland
  • Calgary Scientific Inc., Calgary, Alberta, Canada
  • CerviLenz, Inc, Chagrin Falls, Ohio
  • Circuport, Inc., Morristown, New Jersey
  • Claro Scientific, St. Petersburg, Florida
  • Cohera Medical, Inc., Pittsburgh, Pennsylvania
  • CogniSens, Montreal, Quebec, Canada
  • ConvaTec Inc., Skillman, New Jersey
  • CSA Medical, Baltimore, Maryland
  • CytoPherx, Inc, Ann Arbor, Michigan
  • CytoSorbents Corporation, Monmouth Junction, New Jersey
  • DioGenix, Gaithersburg, Maryland
  • eSight Corporation, Ottawa, Ontario, Canada
  • EastMed Inc, Halifax, Nova Scotia, Canada
  • Echometrix, Madison, Wisconsin
  • EGI, Eugene, Oregon
  • Endosense SA, Geneva, Switzerland
  • Endomimetrics, Birmingham, Alabama
  • Flowsense Medical Ltd., Misgav, Israel
  • GeneEx, Inc., Hialech, Florida
  • Hadasit Medical Research Services & Development Ltd., Jerusalem, Israel
  • Healionics Corporation, Seattle, Washington
  • Healthpoint, Ltd., Fort Worth, Texas
  • Interface Biologics, Toronto, Ontario, Canada
  • Jabil, Inc., St. Petersburg, Florida
  • Lineagen, Inc., Salt Lake City, Utah
  • MONITOR-it S.A., Esch-sur-alzette, Luxembourg
  • NovaScan, Milwaukee, Wisconsin
  • Noxilizer, Inc, Baltimore, Maryland
  • Oncoscope, Inc, Durham, N. Carolina
  • Photo Dynamic Therapy LLC, Vienna, Austria
  • Profound Medical Inc., Toronto, Ontario, Canada
  • Regenesis Biomedical Inc, Scottsdale, Arizona
  • S.E.A. Medical Systems, Inc, Santa Clara, California
  • Semprus BioSciences, Cambridge, Massachusetts
  • SendSor Group, Lafayette, Indiana
  • Sphere Medical, Cambridge, United Kingdom
  • StemCellRX, Chile
  • Tissue Fusion, LLC, Colorado Springs, Colorado
  • TrusTech, Manchester, England
  • ValveXchange, Inc., Aurora, Colorado
  • ZSX Medical, LLC, King of Prussia, Pennsylvania

In addition to the companies listed above, from 2:50 p.m. to 4:50 p.m. Tuesday, October 19, the Coulter Foundation Translational Research Partnership Universities Boston University, Case Western Reserve University, Duke University, Georgia Institute of Technology and Emory University, Stanford University, University of Michigan, University of Maryland, University of Virginia, University of Washington and University of Wisconsin will present 20 innovative and exciting advances solving pressing, unmet clinical needs. These presentations will focus on advances in the following areas cardiovascular, IVD diagnostics, imaging, neurology, ophthalmology, orthopedics, surgical tools, tissue regeneration and wound healing.

“To further assist emerging growth companies and foster innovation, AdvaMed 2010 will host two funding forums on Tuesday, October 19,” said Mr. Richard Holdren, a Texas-based angel investor with Healthcare Angels and AdvaMed 2010 Business Development Committee member. The two forums are titled “Tap Into $2 Billion in Government Funding” and “Venture Funding.” “These forums will focus on the SBIR and STTR federal small business grant and contract programs and today’s venture capital investment environment,” Holdren said.

Pete Shagory, Principal with Baird Venture Partners will lead the Venture Funding forum. Both the National Venture Capital Association and the Angel Capital Association support AdvaMed 2010: The MedTech Conference activities. You may read the article here.